Evidence map›Paper›PMID 40595708›Full record

ArticleScientific reports2025

RBPMS2 can inhibit the NLRP3 / caspase-1 / GSDMD signaling pathway to resist pyroptosis in gastric cancer cells.

Nailin Zhang, Lina Yan, Hua Cao, Nana Zhang, Tong Zhang, Shengjiang Guan, Qiquan Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nailin ZhangDepartment of Spleen and Stomach Diseases, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang, 050000, China.
Lina YanSchool of Public Health, Hebei Medicine University, Shijiazhuang, 050000, China.
Hua CaoGraduate school, Hebei University of Chinese Medicine, Shijiazhuang, 050000, China.
Nana ZhangRespiratory department, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Changan District, Shijiazhuang, 050011, China.
Tong Zhang *Respiratory department, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Changan District, Shijiazhuang, 050011, China. doctong1990@163.com.
Shengjiang Guan *Pharmaceutical Department, Hebei Provincial Hospital of Chinese Medicine, No.389 Zhongshan Road, Changan District, 050011, Shijiazhuang, Hebei, China. guanshengj1@hebcm.edu.cn.
Qiquan Liu *Department of Spleen and Stomach Diseases, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang, 050000, China. Liuqq56@163.com.

Funding

National Project of Clinical Research Base of Traditional Chinese Medicine (2018 State Office of Traditional Chinese Medicine Science and Technology Letter No. 131)Natural Science Foundation of Hebei Province NO.H2024423016Scientific Research Project of Hebei Administration of Traditional Chinese Medicine NO.2023032State Administration of Traditional Chinese Medicine National famous Traditional Chinese Medicine Inheritance Studio construction project (2018 State Office of Traditional Chinese Medicine Teaching Letter No. 119)
6 · The paper itself

Abstract

Gastric cancer (GC) is one of the most common malignancies worldwide, and its development is closely associated with the abnormal expression of numerous genes. RNA - binding protein with multiple splicing 2 (RBPMS2), a member of the RNA - binding protein family, has recently been found to be abnormally activated in GC cells. Meanwhile, pyroptosis, a form of programmed cell death, is related to tumorigenesis, development, and immune responses.This study investigated the role of the RNA - binding protein RBPMS2 in GC. It revealed the high expression of RBPMS2 in GC cells and its association with poor prognosis. RBPMS2 promoted the proliferation, invasion, and migration of GC cells while inhibiting pyroptosis by suppressing the NLR family pyrin domain containing 3 (NLRP3)/caspase - 1/gasdermin (DGSDMD) signaling pathway. Knocking out RBPMS2 activated pyroptosis, leading to cell membrane damage and increased expression of pyroptosis - related proteins. The NLRP3 inhibitor MCC950 reversed these effects, confirming the involvement of this pathway. These findings suggest that RBPMS2 may be a potential therapeutic target for inducing pyroptosis in gastric cancer cells, providing novel insights into treatment strategies for gastric cancer.

Indexed as

Caspase 1Intracellular Signaling Peptides and ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinPhosphate-Binding ProteinsPyroptosisRNA-Binding ProteinsSignal TransductionStomach NeoplasmsCell Line, TumorCell MovementCell ProliferationFemaleFuransGasderminsGene Expression Regulation, NeoplasticHumansCaspase 1FuransGasderminsGSDMD protein, humanIndenesIntracellular Signaling Peptides and ProteinsN-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamideNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanPhosphate-Binding ProteinsRNA-Binding ProteinsSulfonamidesCell migrationCell multiplicationFerroptosisGastric cancerPyrodeathRBPMS2

Identifiers

PMID40595708
PMCPMC12215900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.